IMPACT: IMPact of Antimalarials on Covid-19 Infections in RAPPORT (IMPACT)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04347798 |
Recruitment Status : Unknown
Verified June 2020 by University of Alberta.
Recruitment status was: Enrolling by invitation
First Posted : April 15, 2020
Last Update Posted : June 4, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
Covid-19 Infection Rheumatoid Arthritis Psoriatic Arthritis Hydroxychloroquine | Other: Hydroxychloroquine/Chloroquine |

Study Type : | Observational [Patient Registry] |
Estimated Enrollment : | 500 participants |
Observational Model: | Case-Control |
Time Perspective: | Prospective |
Target Follow-Up Duration: | 12 Months |
Official Title: | IMPACT RAPPORT: IMPact of Antimalarials on Covid Infections: a Case Control sTudy of RAPPORT |
Estimated Study Start Date : | September 2020 |
Estimated Primary Completion Date : | April 2021 |
Estimated Study Completion Date : | April 2021 |

Group/Cohort | Intervention/treatment |
---|---|
Inflammatory arthritis patients on biologic + anti-malarial
Patients in northern Alberta receiving hydroxychloroquine or chloroquine +/- other disease modifying anti-rheumatic drug + biologic (anti-TNF inhibitor or anti-IL-6 blocker or B-cell depletor or JAK kinase inhibitor or T-cell c-stimulation inhibitor or IL-17 blocker)
|
Other: Hydroxychloroquine/Chloroquine
Prospective evaluation of development of Covid-19 in inflammatory arthritis patients on biologics with anti-malarials compared to inflammatory arthritis patients on biologics without anti-malarial exposure |
Inflammatory arthritis patients on biologic + NO anti-malarial
Patients in northern Alberta receiving a biologic (anti-TNF inhibitor or anti-IL-6 blocker or B-cell depletor or JAK kinase inhibitor or T-cell c-stimulation inhibitor or IL-17 blocker) +/- any disease modifying anti-rheumatic drug except for anti-malarials (hydroxychloroquine or chloroquine)
|
- Impact of anti-malarials on the development and severity of Covid-19 in the anti-malarial group compared to the non-anti-malarial group [ Time Frame: 12 months ]Number of patients developing signs and symptoms of Covid-19 or other infections
- Incidence of Covid-19 infection in the anti-malarial group compared to the non-anti-malarial group [ Time Frame: 12 months ]Number of patients developing Covid-19 infection
- Incidence of Covid-19 infection in the sub-groups of patients on biologic agents with different mechanisms of action [ Time Frame: 12 months ]Incidence of Covid-19 infection in the sub-groups of patients on biologic agents with different mechanisms of action
- Quantification of Covid-19 antibodies in anti-malarial vs non-anti-malarial groups of inflammatory arthritis patients [ Time Frame: 6 months ]Quantitative measurement of Covid-19 serology to understand possible differences in degree of immune response adjusted for anti-malarial and/or biologic exposure
Biospecimen Retention: Samples Without DNA

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- Current active and consented patient of the Rheumatoid Arthritis Pharmacovigilance Program of Northern Alberta with an e-mail or mailing address
Exclusion Criteria:
- Unable to read English; not consenting to be contacted for future studies

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04347798
Canada, Alberta | |
University of Alberta | |
Edmonton, Alberta, Canada, T6G 2G3 |
Principal Investigator: | Stephanie O Keeling, MD | University of Alberta | |
Principal Investigator: | Walter P Maksymowych, MD | University of Alberta |
Responsible Party: | University of Alberta |
ClinicalTrials.gov Identifier: | NCT04347798 |
Other Study ID Numbers: |
Pro00100000 |
First Posted: | April 15, 2020 Key Record Dates |
Last Update Posted: | June 4, 2020 |
Last Verified: | June 2020 |
Rheumatoid arthritis Psoriatic arthritis Covid-19 |
Hydroxychloroquine Chloroquine Anti-malarials |
Infections Communicable Diseases COVID-19 Arthritis Arthritis, Rheumatoid Arthritis, Psoriatic Disease Attributes Pathologic Processes Respiratory Tract Infections Pneumonia, Viral Pneumonia Virus Diseases Coronavirus Infections Coronaviridae Infections Nidovirales Infections |
RNA Virus Infections Lung Diseases Respiratory Tract Diseases Joint Diseases Musculoskeletal Diseases Rheumatic Diseases Connective Tissue Diseases Autoimmune Diseases Immune System Diseases Spondylarthropathies Spondylarthritis Spondylitis Spinal Diseases Bone Diseases Psoriasis |